Exclusive: Canada drugmaker Cipher mulls sale – sources

By Carl O’Donnell and John Tilak (Reuters) – Cipher Pharmaceuticals Inc , a Canadian specialty pharmaceuticals manufacturer, has hired an investment bank to review strategic alternatives, including a potential sale, people familiar with the matter said. The strategic review comes amid increased U.S. scrutiny of specialty drug prices, which has weighed on the valuations of many Canadian specialty pharmaceutical companies with U.S. revenues. “The company is working with an advisor to consider various strategic alternatives potentially available to enhance shareholder value, with a focus on the U.S. business,” Cipher said in a press statement following the report.
Go to Source